BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Resverlogix Corporation (RVX.TO) Completes Enrollment Of Phase 2 Clinical Trial Of RVX-208 In Patients With Pre-Diabetes Mellitus


12/23/2013 9:57:33 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CALGARY
, Dec. 23, 2013 /PRNewswire/ - Resverlogix Corp. (TSX:RVX) today announced that it has completed enrollment of its exploratory Phase 2 clinical trial in patients with pre-diabetes mellitus to examine the effects of RVX-208 and ApoA-I production on glucose metabolism. Approximately 80% of patients with diabetes die from cardiovascular disease (CVD), most notably myocardial infarct and stroke. The trial is conducted in collaboration with Baker IDI Heart & Diabetes Institute in Melbourne, Australia. This trial will examine insulin secretion, insulin sensitivity and other parameters of importance in diabetes and cardiovascular disease. A total of twenty patients have been enrolled in Australia, with data expected on time in mid-2014.

The foundation of this trial builds upon the known actions of RVX-208 and the knowledge that this compound triggers a key epigenetic pathway resulting in enhanced ApoA-I protein production to raise the body's level of functional HDL particles. The effect of newly created ApoA-I/HDL may help to improve glucose control through effects on not only pancreatic cells that make and secrete insulin but also muscle, the major site of glucose utilization in the body. These actions have the potential to improve on important risk factors for cardiovascular disease associated with the diabetic state.

"The prevalence of diabetes mellitus is rising at epidemic rates around the world adding to the incidence of cardiovascular disease. The results from our current study will shed important light on the potential of RVX-208, the first compound affecting epigenetics to be tested in potentially reducing CVD-risk in patients with diabetes mellitus." said Dr. Norman Wong, Chief Scientific Officer of Resverlogix.

Principal Investigator, Professor Bronwyn Kingwell said, "This work builds on a strong evidence base regarding novel actions of HDL on glucose control. If positive, these studies will support therapeutic approaches to raise levels of circulating HDL to help reduce CVD-risk and further improve management of Type II Diabetes and its complications."

About RVX-208

RVX-208 is a first-in-class small molecule that inhibits BET bromodomains. RVX-208 functions by removing atherosclerotic plaque via reverse cholesterol transport (RCT), the natural process through which atherosclerotic plaque is transported out of the arteries and removed from the body by the liver. RVX-208 increases production of Apolipoprotein A-I (ApoA-I), the key building block of functional high-density lipoprotein (HDL) particles and the type required for RCT. These newly produced, functional HDL particles are flat and empty and can efficiently remove plaque and stabilize or reverse atherosclerotic disease. Analysis of recent clinical trials data showed that RVX-208 significantly reduces coronary atherosclerosis and major adverse cardiac events in patients with CVD who have a low level of HDL and elevated CRP, a population with unmet medical need. ApoA-I may also exert beneficial effects in Alzheimer's disease and Diabetes Mellitus.

About Resverlogix

Resverlogix Corp. (TSX:RVX) is a clinical stage biotechnology company developing compounds involving ApoA-I production. RVX-208 is a first-in-class small molecule in development for the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. RVX-208 is the first BET bromodomain inhibitor in clinical trials. Resverlogix's common shares trade on the Toronto Stock Exchange (TSX: RVX). For further information please visit www.resverlogix.com. We can be followed on our blog at http://www.resverlogix.com/blog.

Resverlogix IR App

This app gives Resverlogix investors mobile access to the latest stock data, news, and SEC Filings. It also provides proprietary company content including presentations, conference calls, videos, fact sheets, annual reports and other qualitative company information. Investors are able to receive 'push' notifications when new content is added to the IR App such as add events to calendars, share content and as well as download files for offline viewing.

To download the Resverlogix IR App, please visit your app store.

Apple Products (iPhone, iPad, and iPod's) - https://itunes.apple.com/WebObjects/MZStore.woa/wa/viewSoftware?id=730718904&mt=8

Android Products (Google Play, Tablets and Smartphones) - https://play.google.com/store/apps/details?id=com.theirapp.resverlogix

This news release may contain certain forward-looking information as defined under applicable Canadian securities legislation, that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates", "plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions. In particular, this news release includes forward looking information relating to research and development activities and the potential role of RVX-208 in the treatment of diseases such as atherosclerosis, Diabetes Mellitus and Alzheimer's disease. Our actual results, events or developments could be materially different from those expressed or implied by these forward-looking statements. We can give no assurance that any of the events or expectations will occur or be realized. By their nature, forward-looking statements are subject to numerous assumptions and risk factors including those discussed in our Annual Information Form and most recent MD&A which are incorporated herein by reference and are available through SEDAR at www.sedar.com. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Company Contacts:
Donald J. McCaffrey Kenneth Lebioda
President and CEO SVP Business & Corporate Development
Resverlogix Corp. Resverlogix Corp.
Phone: 403-254-9252 Phone: 403-254-9252
Email: don@resverlogix.com Email: ken@resverlogix.com

SOURCE Resverlogix Corp.



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES